Company Disclosure: Quarterly Financial Results

Financial Performance Highlights (Consolidated)

Q2 FY27 Performance (Quarter Ended September 30, 2026)

  • Revenue: ₹874 Cr, increased by 19.6% YoY (from ₹731 Cr in Q2 FY26)
  • EBITDA: ₹280 Cr, increased by 25.1% YoY (from ₹224 Cr in Q2 FY26)
  • EBITDA Margin: 32.1% (vs 30.7% in Q2 FY26)
  • PAT: ₹194 Cr, increased by 27.5% YoY (from ₹152 Cr in Q2 FY26)
  • PAT Margin: 22.2% (vs 20.8% in Q2 FY26)
  • EPS: ₹11.5, increased by 27.5% YoY (from ₹9.0 in Q2 FY26)

H1 FY27 Performance (Half Year Ended September 30, 2026)

  • Revenue: ₹1,672 Cr, increased by 19.4% YoY (from ₹1,400 Cr in H1 FY26)
  • EBITDA: ₹528 Cr, increased by 26.7% YoY (from ₹416 Cr in H1 FY26)
  • EBITDA Margin: 31.6% (vs 29.7% in H1 FY26)
  • PAT: ₹364 Cr, increased by 27.3% YoY (from ₹286 Cr in H1 FY26)
  • PAT Margin: 21.8% (vs 20.4% in H1 FY26)
  • EPS: ₹21.7, increased by 27.6% YoY (from ₹17.0 in H1 FY26)

Detailed Financial Breakdown (Consolidated, ₹ Cr)

Expense Analysis Q2 FY27

  • Material consumed: ₹162 Cr (vs ₹142 Cr in Q2 FY26)
  • Employee benefit Expenses: ₹139 Cr (vs ₹124 Cr in Q2 FY26)
  • Fees to collection centres: ₹129 Cr (vs ₹109 Cr in Q2 FY26)
  • Other Expenses: ₹164 Cr (vs ₹132 Cr in Q2 FY26)
  • Total Expenses: ₹594 Cr, increased by 17.2% YoY (from ₹507 Cr in Q2 FY26)

Other Financial Items Q2 FY27

  • Other Income: ₹34 Cr (vs ₹25 Cr in Q2 FY26)
  • Depreciation Cost: ₹47 Cr (vs ₹41 Cr in Q2 FY26)
  • Finance Cost: ₹7 Cr (vs ₹5 Cr in Q2 FY26)
  • PBT: ₹261 Cr, increased by 28.1% YoY (from ₹204 Cr in Q2 FY26)
  • PBT Margin: 29.8% (vs 27.9% in Q2 FY26)
  • Income Tax: ₹67 Cr (vs ₹51 Cr in Q2 FY26)

Corporate Actions

  • Interim Dividend: Declared 50% dividend, amounting to ₹5 per share

Liquidity Position

  • Cash and Cash equivalents: ₹1,746 Cr as on September 30, 2026

Operational Overview

As of March 31, 2026, the company operates:

  • 312 clinical laboratories (including National Reference Lab at Delhi, Regional Reference Labs at Kolkata, Bangalore & Mumbai)
  • 7,727 Patient Service Centers (PSCs)
  • 13,935 Pick-up Points (PUPs)

Business Description

Dr Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. The company offers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.

Forward-Looking Statements Disclaimer

The release contains forward-looking statements relating to implementation of strategic initiatives and future business developments and economic performance. The company notes that actual results could differ materially from expectations due to market conditions, macroeconomic factors, regulatory trends, currency movements, competitive pressures, technological developments, and other unknown factors.